Fulford Daniel, Marsch Lisa A, Pratap Abhishek
Sargent College of Health & Rehabilitation Sciences, Boston University, Boston, Massachusetts; Psychological & Brain Sciences, Boston University, Boston, Massachusetts.
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.
Biol Psychiatry. 2024 Oct 15;96(8):659-665. doi: 10.1016/j.biopsych.2024.06.026. Epub 2024 Jul 1.
Digital therapeutics-web-based programs, smartphone applications, and wearable devices designed to prevent, treat, or manage clinical conditions through software-driven, evidence-based intervention-can provide accessible alternatives and/or may supplement standard care for patients with serious mental illnesses, including schizophrenia. In this article, we provide a targeted summary of the rapidly growing field of digital therapeutics for schizophrenia and related serious mental illnesses. First, we define digital therapeutics. Then, we provide a brief summary of the emerging evidence of the efficacy of digital therapeutics for improving clinical outcomes, focusing on potential mechanisms of action for addressing some of the most challenging problems, including negative symptoms of psychosis. Our focus on these promising targets for digital therapeutics, including the latest in prescription models in the commercial space, highlights future directions for research and practice in this exciting field.
数字疗法——基于网络的程序、智能手机应用程序以及旨在通过软件驱动的、循证干预来预防、治疗或管理临床病症的可穿戴设备——可以为包括精神分裂症在内的严重精神疾病患者提供可及的替代方案和/或补充标准护理。在本文中,我们针对精神分裂症及相关严重精神疾病这一快速发展的数字疗法领域提供了一份有针对性的综述。首先,我们对数字疗法进行了定义。然后,我们简要总结了数字疗法在改善临床结局方面疗效的新证据,重点关注解决一些最具挑战性问题(包括精神病性阴性症状)的潜在作用机制。我们对数字疗法这些有前景的靶点的关注,包括商业领域最新的处方模式,突出了这一令人兴奋的领域未来的研究和实践方向。